
3 minute read
Opinion of the Director
Cheap is Expansive
In this edition of Clinical Research Insider, we will review the topics related to drugs marketed with no proven efficacy or safety in their development phases. This is a common matter in countries that do not yet have a robust health surveillance system; You always end up acquiring the cheapest option or the option available in the local market, beyond the constant search to find out if that drug or medical device obtained the permits required to be sold in that specific domestic market.
Advertisement
It seems to us to be an issue of the utmost importance, for it can become a public health issue; Drugs or medical devices that are apocryphal, or with little scientific validity, can put the lives of the people who consume them at risk. Without data on the efficacy and safety profile of the drug, dietary supplement, or medical device, the risk of severe adverse events, lack of efficacy, or drug interactions is in doubt.
Our sister companies have spent lots of effort and dedication in developing new strategies for pharmaceutical companies or medical device developers to generate efficacy data and build a safety profile for each product intended for international markets. In addition, there are real efforts by regulatory entities to fight against this phenomenon.
The efforts to push for good practices in the development of medicines must come from various spheres, starting from the developers themselves to those who provide scientific data and the public avoiding the purchase of these products.
Within social wisdom, it is believed that certain products derived from plants and animal oils can be beneficial to health, as they have been used since ancient times to cure various ills. While this may be correct, when we work on developing a product derived from those mentioned sources, it is important to know that the alkaloid extracted is no longer in its natural state and the percentage of it may vary; We do not know what the maximum effective dose may be to achieve a therapeutic effect. Will we be aware of what we could cause by bringing such a product to market?
I end with an invitation to all those business owners or entrepreneurs who are thinking of placing a pharmaceutical product or medical device on the market, rest assured that testing the safety and efficacy of the product will give them in addition to the necessary approvals in all the countries in which they want to enter, as well as necessary data to sustain or develop your competitive advantage over your competitors.
And for the end users of the products? We invite you to investigate the product you have purchased, review how its effectiveness was proven, and what kind of safety profile has. Only then we will find better products on the market.
Marco Cid

CEO Drox Health Science – CEO Clinical Research Insider
Chemist-pharmacist Biologist from La Salle University, MBA from ITESO, postgraduate in clinical research from York College, and Senior Management from the InnovAD Program of IPADE. Expert in research and development of drug products; entrepreneur, founder of several for-profit and non-profit associations, and creator of a private equity investment company.